Background {#Sec1}
==========

Among patients newly diagnosed with non-small cell lung cancer (NSCLC) in developed countries, approximately 50% are ≥70 years at the time of diagnosis \[[@CR1]\], and 30%--40% are with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2 \[[@CR2]\]. Because older age and poor PS have often been related to the increased risk of toxicity associated with cytotoxic chemotherapy, such patients have often been excluded from clinical trials. To note, some randomized phase 3 trials of single-agent therapy have been conducted for elderly, advanced NSCLC patients. In the Elderly Lung Cancer Vinorelbine Italian Study (ELVIS), median overall survival (OS) was significantly better in the vinorelbine group than that in the best supportive care (BSC) group \[[@CR3], [@CR4]\]. The Multicenter Italian Lung Cancer in the Elderly Study (MILES) revealed that median OS in the gemcitabine group was almost equal to that in the vinorelbine group \[[@CR5]\]. Subsequently, the WJTOG9904 trial \[[@CR6]\] showed that patients treated with docetaxel had a significantly higher response rate and better progression-free survival (PFS) compared with patients taking vinorelbine. However, the difference in OS was not statistically significant, and severe neutropenia was more common with docetaxel. In addition, trials of platinum-based doublet therapy have also been conducted in elderly patients. In a French Intergroup Study (IFCT-0501), OS was significantly betterin the carboplatin plus weekly paclitaxel group than that in the single-agent therapy (gemcitabine or vinorelbine) group \[[@CR7]\]. However, grade ≥ 3 neutropenia and treatment-related death was more common with carboplatin plus weekly paclitaxel compared with single-agent therapy. Based on these trial results, single-agent therapy (docetaxel, gemcitabine, or vinorelbine) was recommended as first-line treatment for elderly, advanced NSCLC patients without known driver mutations, and carboplatin-based doublet therapy may be a viable option in patients deemed able to tolerate such therapy. However, little is known concerning chemotherapy in elderly, advanced NSCLC patients with poor PS, and the usefulness of chemotherapy for such patients remains unclear. Moreover, elderly patients who are enrolled in clinical trials represent a carefully selected subset. In clinical practice, elderly patients are a more heterogeneous population, with baseline organ dysfunctions and variable comorbidities, and the PS alone is not sufficient enough to account for the heterogeneity within elderly patients. It is critically important to identify patient populations that can receive a survival benefit of systemic chemotherapy in elderly patients with poor PS. In the present study, we retrospectively reviewed consecutive elderly patients (≥75 years of age) with advanced NSCLC and with poor PS (ECOG PS ≥ 2) to identify factors that predict the survival benefit of cytotoxic chemotherapy.

Methods {#Sec2}
=======

Patients and settings {#Sec3}
---------------------

All consecutive patients enrolled were (1) pathologically or cytologically confirmed NSCLC; (2) at stage IIIB or IV according to the 7th edition TNM classification; (3) ≥75 years of age; (4) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥ 2; (5) with an epidermal growth factor receptor mutation wild type or unknown status; and (6) newly diagnosed at the Kurashiki Central Hospital (Kurashiki city, Okayama, Japan) from January 2009 to December 2012. The exclusion criteria included clinical diagnosis of lung cancer without pathological or cytological confirmation. In patients with ECOG PS ≥ 3, chemotherapy could be carried out only when the patient was diagnosed as treatable and tolerable for chemotherapy by the attending physician, and the patient and family were strongly hoping for the chemotherapy, even though they knew all the risks. This study has been carried out in accordance with the Declaration of Helsinki. The Ethics Committee of the Kurashiki Central Hospital approved the study protocol, and patient consent was waived because this was a retrospective study and anonymity was secured.

Clinical and laboratory findings {#Sec4}
--------------------------------

Clinical and laboratory data used in this study were retrieved from patient medical records and included age; gender; the ECOG PS; smoking status; comorbidities; tumor histology; cancer stage; major diameter of the primary site; metastatic organs (brain, bone, liver, and adrenal gland); laboratory data such as white blood cell, neutrophil, and lymphocyte counts as well as hemoglobin, albumin, lactate dehydrogenase, serum calcium, and C-reactive protein levels; treatment status; progression free survival (PFS) of initial treatment; and OS. The OS was defined as the length of time from the date of diagnosis to death of any cause.

Statistical analysis {#Sec5}
--------------------

Categorical data are presented as numbers (percentages), whereas continuous data are presented as medians (interquartile ranges). Fisher's exact test was used to compare categorical data, and the Mann--Whitney U test was used to compare continuous data. Cumulative survival probabilities were estimated using the Kaplan-Meier method. The log-rank test was used to compare survival among patient groups. A multivariate analysis using a Cox proportional hazard model was performed to identify the factors associated with survival. A multivariate logistic regression analysis was performed to verify the risk factor for a categorical dependent variable. The factors with *p*-values \<0.05 in univariate analysis were selected as candidate factors of multivariate analysis. A receiver operating characteristic (ROC) curve analysis was used to determine the optimal cut-off values for the risk factor; values with maximum joint sensitivity and specificity were selected. A *p*-value of \<0.05 was considered statistically significant.

Results {#Sec6}
=======

Baseline characteristics and prognoses in the study population {#Sec7}
--------------------------------------------------------------

In the present study, 59 patients were enrolled. Thirty-one patients received at least one chemotherapy regimen (chemotherapy group), whereas 28 patients received best supportive care (BSC) alone (BSC group). Patients' characteristics are summarized in Table [1](#Tab1){ref-type="table"}. The proportion of PS 2, lymphocyte count, and serum albumin level were significantly higher in the chemotherapy group than in the BSC group. No significant differences were observed regarding other clinical and laboratory data. A comparison of survival curves is shown in Fig. [1](#Fig1){ref-type="fig"}. The OS was better in the chemotherapy group than in the BSC group (median OS of 4.7 months and 3.1 months, *p* = 0.0119).Table 1Baseline characteristics of the study populationChemotherapy (*N* = 31)Best supportive care (*N* = 28)*p*-valueAge78.0 \[76.5--80.0\]80.5 \[77.0--84.3\]0.118Gender (male/female)4 / 274 / 241.00ECOG Performance Status (2/3/4)18/12/18/15/50.0350Smoking history30 (96.8%)22 (78.6%)0.0870Brinkman Index1100 \[780--1550\]800 \[420--1395\]0.113Comorbidities Emphysema (%)26 (83.9%)20 (71.4%)0.348 Interstitial pneumonia (%)1 (3.2%)1 (3.6%)1.00 Diabetes mellitus (%)13 (41.9%)1 (3.6%)0.00100Histology (Non-Squamous/Squamous)6 / 256 / 221.00Staging (IIB/IV)5 / 262 / 260.428Major diameter of the primary site39.5 \[27.5--65.0\]52.0 \[40.5--74.0\]0.0740Metastatic organ Brain (%)6 (19.4%)4 (14.3%)0.734 Bone (%)10 (32.3%)6 (21.4%)0.393 Liver (%)3 (9.7%)3 (10.7%)1.00 Adrenal gland (%)4 (12.9%)1 (3.6%)0.356Laboratory data White blood cell count7800 \[6450--9700\]7700 \[6175--11,925\]0.802 Neutrophil count5336 \[4502--6684\]5988 \[4513--8929\]0.362 Lymphocyte count1396 \[1148--1721\]1086 \[848--1432\]0.0370 Hemoglobin12.4 \[11.0--14.0\]12.0 \[11.5--13.2\]0.885 Albumin3.60 \[3.20--3.95\]3.30 \[2.85--3.62\]0.0460 Lactate dehydrogenase214 \[188--247\]247 \[206--277\]0.141 Calcium9.20 \[9.00--9.55\]9.00 \[8.47--9.33\]0.093 C-reactive protein1.81 \[0.66--3.92\]3.20 \[0.57--7.59\]0.391Categorical data are presented as numbers (percentages) whereas continuous data are presented as medians (interquartile ranges). Fisher's exact test was used to compare categorical data, and the Mann--Whitney U test was used to compare continuous dataAbbreviations: *ECOG* Eastern Cooperative Oncology Group Fig. 1A comparison of survival curves between chemotherapy and BSC groups. A comparison of survival curves is shown. The overall survival (OS) was better in the chemotherapy group than in the BSC group

Treatment details and prognosis in the chemotherapy group {#Sec8}
---------------------------------------------------------

Treatment details in the chemotherapy group are shown in Table [2](#Tab2){ref-type="table"}. Twenty of the 31 patients (64.5%) received single-agent therapy, whereas 11 of the 31 patients (35.5%) received carboplatin-based doublet therapy. Patients who received carboplatin-based doublet therapy had higher response rates, and the median PFS values were better. No significant differences were observed in the disease control rate and median number of treatment cycles. An adverse event was the most common cause of cessation in patients receiving single-agent therapy, whereas, in patients receiving carboplatin-based doublet therapy, completion of 4--6 courses was the most common, followed by an adverse event. With regard to OS, log-rank testing did not show statistically significant differences between the single-agent therapy and carboplatin-based doublet therapy groups (median OS of 3.80 months and 7.00 months, *p* = 0.773) (Fig. [2a](#Fig2){ref-type="fig"}). On the other hand, the OS of patients receiving chemotherapy for only 1 cycle was significantly shorter than patients receiving chemotherapy for ≥2 cycles (median OS of 3.0 months and 11.6 months, *p* = 0.0000241) (Fig. [2b](#Fig2){ref-type="fig"}).Table 2Treatment details and prognoses of first-line chemotherapySingle-agent (*N* = 20)Platinum doublet (*N* = 11)Regimen Gemcitabine8 (40.0%)0 Vinorelbine6 (30.0%)0 Docetaxel5 (25.0%)0 Pemetrexed1 (5.0%)0 Carboplatin + weekly paclitaxel09 (81.8%) Carboplatin + gemcitabine01 (9.1%) Carboplatin + S-101 (9.1%)Response rate (%)045.4%Disease control rate (%)55.0%54.5%Progression free survival (month)2.87 \[0.60--7.27\]5.43 \[1.58--8.07\]Number of treatment cycles2.00 \[1.00--2.25\]3.00 \[1.00--4.00\]Early termination (only 1 cycle) (%)7 (35.0%)4 (36.4%)Cause of cessation Adverse event11 (55.0%)4 (36.4%) Deterioration of physical condition5 (25.0%)0 Completion of 4--6 cycles05 (45.5%) Progressive disease3 (15.0%)1 (9.1%) Patient's request1 (5.0%)1 (9.1%)Categorical data are presented as numbers (percentages) whereas continuous data are presented as medians (interquartile ranges) Fig. 2Log-rank testing in the chemotherapy group. Log-rank testing did not show statistically significant differences in median overall survival (OS) between single-agent therapy and carboplatin-based doublet therapy groups (**a**). To note, the OS of patients who received chemotherapy for only 1 cycle was significantly shorter than those of patients who received chemotherapy for ≥2 cycles (**b**)

Risk factors for the early termination of chemotherapy {#Sec9}
------------------------------------------------------

Eleven patients received chemotherapy for only 1 cycle (early termination group), whereas 20 patients received chemotherapy for ≥2 cycles (continuous treatment group). When comparing the clinical and laboratory data between two groups (Additional file [1](#MOESM1){ref-type="media"} Table S1), the incidence of bone metastasis was higher and serum albumin levels were lower in the early termination group than in the continuous treatment group. No significant differences were observed for any other clinical and laboratory data.

A logistic regression analysis was performed to verify the risk factor for the early termination of chemotherapy (Table [3](#Tab3){ref-type="table"}). In univariate analysis, serum albumin level and the existence of bone metastasis, all with *p*-values \<0.05, were selected as candidate risk factors. A multivariate analysis showed that low serum albumin level and the existence of bone metastasis were significantly associated with the early termination of chemotherapy (*p* = 0.0493 and 0.0174, respectively).Table 3Logistic regression analysis verifying the risk factors for early termination of chemotherapy (*N* = 31)Odds ratio95% confidence interval*p*-valueUnivariate analysis Age0.930.722--1.200.575 ECOG Performance status = 20.4490.100--2.010.295 Brinkman Index1.000.999--1.000.655 Emphysema0.7940.112--5.660.818 Diabetes melitus2.230.497--10.00.295 Squamous cell carcinoma0.8890.135--5.850.902 Major diameter of the primary site1.010.973--1.040.672 Brain metastasis2.120.349--13.00.414 Bone metastasis9.921.75--56.30.00961 Liver metastasis0.9000.0723--11.20.935 Adrenal gland metastasis7.120.640--79.30.110 Carboplatin-based doublet therapy1.060.229--4.920.939 Lymphocyte count10.999--1.000.866 Hemoglobin0.6370.392--1.040.0691 Albumin0.1170.0168--0.8110.0299 Lactate dehydrogenase1.010.999--1.020.0979 Calcium1.190.632--2.240.59 C-reactive protein1.150.897--1.480.267Multivariate analysis Bone metastasis10.91.52--77.90.0174 Albumin0.08860.00791--0.9920.0493In the univariate analysis, serum albumin level and the existence of bone metastasis, all with *p*-values \<0.05, were selected as candidate risk factors. A multivariate analysis showed that the association between serum albumin level and the existence of bone metastasis with early termination of chemotherapy were statistically significantAbbreviations: *ECOG* Eastern Cooperative Oncology Group

The prognostic factors in the chemotherapy group {#Sec10}
------------------------------------------------

An analysis using a Cox proportional hazard model was performed to verify the prognostic factor associated with survival in the chemotherapy group (Table [4](#Tab4){ref-type="table"}). In univariate analysis, serum albumin level, number of cycles, the existence of bone metastasis, and the existence of adrenal gland metastasis, all with *p*-values \<0.05, were selected as candidate factors. A multivariate analysis identified the serum albumin level as an independent factor associated with survival \[hazard ratio: 0.174; 95% confidence interval (CI): 0.0610--0.495; *p* = 0.00104\].Table 4Analysis using a Cox proportional hazard model to verify the prognostic factor associated with survival in the chemotherapy group (*N* = 31)Hazard ratio95% confidence interval*p*-valueUnivariate analysis Age0.9950.884--1.120.929 ECOG Performance status = 20.9940.453--2.180.987 Brinkman Index0.9990.998--1.000.104 Emphysema0.6490.241--1.740.391 Diabetes mellitus0.9900.448--2.1890.980 Squamous cell carcinoma1.150.420--3.120.792 Major diameter of the primary site1.020.997--1.030.102 Brain metastasis2.820.986--8.040.0533 Bone metastasis3.071.24--7.570.0150 Liver metastasis1.290.294--5.650.736 Adrenal gland metastasis4.771.21--18.80.0253 Carboplatin-based doublet therapy1.120.513--2.460.773 Number of treatment cycles0.6650.483--0.9150.0122 Lymphocyte count1.000.999--1.000.321 Hemoglobin0.7890.621--1.000.0511 Albumin0.1800.0694--0.4650.000408 Lactate dehydrogenase1.000.998--1.000.455 Calcium1.150.764--1.720.51 C-reactive protein1.080.961--1.210.196Multivariate analysis Bone metastasis1.980.666--5.900.2190 Adrenal gland metastasis2.190.470--10.170.3180 Number of treatment cycles0.7440.518--1.070.110 Albumin0.180.0638--0.5080.00121In the univariate analysis, serum albumin level, number of cycles, the existence of bone metastasis, and the existence of adrenal gland metastasis, all with *p*-values \<0.05, were selected as candidate factors. A multivariate analysis identified serum albumin level as an independent factor associated with survivalAbbreviations: *ECOG* Eastern Cooperative Oncology Group

Best cut off value for the serum albumin level {#Sec11}
----------------------------------------------

To determine the cut-off values of serum albumin level for the "early termination of chemotherapy," an ROC curve analysis was performed. The area under the curve for the serum albumin level was 0.752 (95% CI: 0.570--0.934) and the cut-off value for which sensitivity + specificity was maximal was 3.40 g/dL (81.8% sensitivity and 70.0% specificity).

In addition, we performed a ROC curve analysis to determine the cut-off values of serum albumin level for "death within 3 months" in the chemotherapy group, which was based on the median OS of 3.1 months in the BSC group in the present study. The area under the curve for the serum albumin level was 0.739 (95% CI: 0.531--0.947) and the cut-off value for which sensitivity + specificity was maximal was also 3.40 g/dL (87.5% sensitivity and 65.2% specificity).

Comparison of survival curves based on serum albumin levels {#Sec12}
-----------------------------------------------------------

We compared the survival curves between the BSC and chemotherapy groups based on the serum albumin level. For patients with serum albumin levels ≥3.40 g/dL, OS was significantly better in the chemotherapy group than that in the BSC group (respective median OS of 12.7 months and 3.9 months, *p* = 0.0156) (Fig. [3a](#Fig3){ref-type="fig"}). In patients with serum albumin levels \<3.40 g/dL, the OS did not differ between the chemotherapy and BSC groups (respective median OS of 3.3 months and 2. 7 months, *p* = 0.620) (Fig. [3b](#Fig3){ref-type="fig"}).Fig. 3Comparison of survival curves based on serum albumin levels**.** In the patients with serum albumin levels ≥3.40 g/dL, overall survival (OS) was significantly better in the chemotherapy group than that in the BSC group (**a**); in patients with serum albumin levels \<3.40 g/dL, the OS did not differ between chemotherapy and BSC groups (**b**)

Discussion {#Sec13}
==========

The present study demonstrated the following three important clinical observations. First, the OS of the chemotherapy group was better than that of the BSC group in elderly patients with poor PS. Second, the number of treatment cycles had a larger impact on the survival benefit of chemotherapy than the decision/selection of either single-agent therapy or carboplatin-doublet therapy. Third, hypoalbuminemia was not only the risk factor for early termination of chemotherapy, but also the independent prognostic factor in the chemotherapy group.

The clinician-estimated PS is the most common method to evaluate physiologic reserve and functional status in NSCLC patients, and it is used to assess a patient's tolerability against chemotherapy. In previous clinical trials conducted for elderly, advanced NSCLC patients, such as the ELVIS and IFCT-0501 trials \[[@CR3], [@CR4], [@CR7]\], 20--30% of patients had a PS of 2, whereas almost no data were available for patients with PS ≥ 3. Given this, there is a general consensus that elderly patients with PS 2 who wish to receive treatment should be offered chemotherapy, and elderly patients with PS ≥ 3 should receive supportive care aimed at maintaining quality of life \[[@CR8]\]. In the present study, because of the differences in the baseline characteristics between the chemotherapy and BSC groups, it cannot be simply considered that chemotherapy prolonged OS in elderly patients with poor PS. However, meta-analysis of the clinical trials comparing chemotherapy and BSC for advanced NSCLC demonstrated that chemotherapy improves OS even in patients with poor PS \[[@CR9]\]. Moreover, when comparing patients with PS 2 and PS ≥ 3 in the chemotherapy group of the present study, there were no significant differences in the median number of initial treatment cycles (2 cycles each), disease control rates of the initial treatment (64.7% in PS 2 and 66.7% in PS ≥ 3), and median OS (6.50 months in PS 2 and 4.00 months in PS ≥ 3, *p* = 0.987), regardless of the chemotherapy regimen. These results indicated that PS tends to be insufficient for assessing tolerability against chemotherapy and prognosis in elderly patients. Thus, there would be a certain population within elderly patients with poor PS to benefit via survival due to systemic chemotherapy. Especially in elderly patients, PS easily fluctuates based on various factors, such as pain caused by cancer; thus, treatment decision-making should not be made based on temporal PS alone.

When performing chemotherapy, the optimal regimen for elderly patients with poor PS remains controversial. Carboplatin-based doublet therapy is clearly superior to single-agent therapy regarding antitumor effect, but it results in higher toxicity. In the present study, the response rate was higher and PFS was better in the carboplatin-doublet patient group than the response rate and PFS in the single-agent group (Table [2](#Tab2){ref-type="table"}). However, there were no significant differences observed in the OS between the two groups (Fig. [2a](#Fig2){ref-type="fig"}). In previous randomized control trials designed for elderly populations tasked to compare non-platinum single agent and platinum-doublet therapies, only the IFCT-0501 trial showed the survival benefit of carboplatin plus weekly paclitaxel, even in patients with PS 2 \[[@CR7]\], whereas other trials did not show statistically significant differences in OS \[[@CR10]--[@CR12]\]. In a real-world setting, patients were more heterogeneous and the proportion of frail patients was higher than those in clinical trials, thus the results of IFCT-0501 cannot apply entirely to the elderly population, especially patients with poor PS. The present study also revealed that the OS was significantly shorter in the early termination group than that in the continuous treatment group. Thus, for elderly patients with poor PS, consideration should be given to reasonably choose single-agent therapy, with low toxicity and continuation of as many cycles as possible.

For the treatment decision-making in elderly patients, geriatric assessment, including physical function, comorbidities, psychological state, social support, cognitive function, nutrition, and polypharmacy, is needed in conjunction with PS. Comprehensive geriatric assessment (CGA) has been adopted to evaluate elderly patients with cancer and may help identify patients who are fit and more likely to benefit from chemotherapy \[[@CR13]\]. However, the recent ESOGIA-GFPC-GECP 08--02 trial in elderly patients with advanced NSCLC failed to show a survival benefit of CGA-based strategy in spite of significantly fewer treatment failures attributed to toxicity \[[@CR14]\]. In the present study, hypoalbuminemia was significantly associated with early termination of chemotherapy, and the patients without hypoalbuminemia received a significant survival benefit from chemotherapy. As one of the factors contributing to early termination, hypoalbuminemia was reported to correlate with grade ≥ 3 non-hematological toxicity in elderly NSCLC patients \[[@CR15]\]. On the other hand, the present study revealed that hypoalbuminemia was independently associated with survival in the chemotherapy group, and patients with hypoalbuminemia exhibited poor prognosis regardless of presence or absence of chemotherapy. Previous epidemiological works dissecting the association between pretreatment serum albumin levels and survival in NSCLC revealed that higher serum albumin levels were associated with better survival \[[@CR16]--[@CR23]\]. From these results, it was speculated that serum albumin level predicts the survival benefit of chemotherapy in elderly, advanced NSCLC patients with poor PS. In the CGA measurement tools, body mass index was often used for the assessment of nutrition status, whereas the serum albumin level was rarely used. The assessment tool including the serum albumin level, such as the Chemotherapy Risk Assessment Scale for High age (CRASH) score \[[@CR15]\], may help identify patients more likely to benefit from chemotherapy.

A limitation of the present study was the retrospective single-center study design. Additionally, the number of included patients was small and the distribution of patients may have been skewed. There is a need to accumulate more cases from a plurality of hospitals and conduct further investigations for the validation of the present results. Factors associated with geriatric assessment, such as psychological state, social support, and cognitive function, were not fully evaluated. We might have to consider that prolongation of OS as an optimal endpoint for elderly, advanced NSCLC patients with poor PS.

Conclusions {#Sec14}
===========

In elderly, advanced NSCLC patients with poor PS, serum albumin levels may help identify certain populations more likely to receive a survival benefit of systemic chemotherapy.
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===============
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CRASH
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:   progression-free survival

PS

:   performance status

ROC

:   receiver operating characteristic

**Electronic supplementary material**

The online version of this article (10.1186/s12885-017-3814-3) contains supplementary material, which is available to authorized users.

The authors would like to thank Morihito Takita and Atsuko Yoshizawa (Center for Advancing Translational Sciences, Kanagawa Prefectural Hospital Organization, Japan) for their advice concerning the statistical analysis.

Funding {#FPar1}
=======

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Availability of data and materials {#FPar2}
==================================

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

SIked, HY, and TI were involved in study concepts and design. SI (corresponding author), HY, SIkeo, MM, NS, TN, AN, and TY were involved in data acquisition; SIkeda and HY were involved in the quality control of data and algorithms; SIkeda, HY, SIkeo, MM, NS, TN, AN, TY, AS, TO, and TI were involved in the analysis and interpretation of the clinical data; SIkeda was involved in the statistical analysis; and SIkeda, HY, SIkeo, AS, TO, and TI were involved in drafting the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate {#FPar3}
==========================================

This study has been carried out in accordance with the Declaration of Helsinki. The Ethics Committee of the Kurashiki Central Hospital approved the study protocol. The Ethics Committee of the Kurashiki Central Hospital waived patient consent because this was a retrospective study and anonymity was secured.

Consent for publication {#FPar4}
=======================

Not applicable.

Competing interests {#FPar5}
===================

S Ikeda, H Yoshioka, S Ikeo, M Morita, N Sone, T Niwa, A Nishiyama, T Yokoyama, A Sekine, T Ogura, and T Ishida declare that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Publisher's Note {#FPar6}
================

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
